8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 3, 2021

PETMED EXPRESS, INC.

(Exact name of Registrant as specified in its charter)

Commission file number: 000-28827

Florida	65-0680967
(State or other jurisdiction of incorporation)	(I.R.S. Employer Identification number)

420 South Congress Avenue, Delray Beach, FL 33445

(Address of principal executive offices)                 (zip code)

Registrant's telephone number, including area code: (561) 526-4444

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock, par value $.001 per share	PETS	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed, on May 28, 2021, the Board of Directors (“Board”) of PetMed Express, Inc. (“Company”) notified Menderes Akdag, President and Chief Executive Officer of the Company, that the Company will not extend Mr. Akdag’s employment agreement with the Company and that the employment agreement would therefore end on July 30, 2021, in accordance with the scheduled end date of the agreement.

On July 3, 2021, the Board appointed Bruce S. Rosenbloom, the Company’s Chief Financial Officer, as Interim Chief Executive Officer (principal executive officer) and President of the Company, effective upon Mr. Akdag’s departure until a permanent successor Chief Executive Officer is appointed. Mr. Rosenbloom, age 52, has served as the Chief Financial Officer and Treasurer of the Company since May 2001, and he will continue in those roles. Prior to joining the Company, Mr. Rosenbloom served as the Manager of Finance and Financial Reporting of Cooker Restaurant Corporation, a publicly held (PS: CGRTQ) restaurant, in West Palm Beach, Florida, from December 2000 until May 2001. Mr. Rosenbloom's duties included all internal and external reporting including all SEC filings and annual reports to stockholders. Mr. Rosenbloom was a senior audit accountant for Deloitte & Touche LLP, an international accounting firm, West Palm Beach, Florida, from January 1996 until December 2000. Mr. Rosenbloom was responsible for planning and conducting all aspects of audit engagements for clients in various industries, including direct marketing, healthcare, manufacturing, financial institutions, and professional service firms. In 2018, Mr. Rosenbloom was selected as a South Florida Business Journal’s CFO of the Year award finalist. Mr. Rosenbloom, a certified public accountant, holds a Bachelor of Science degree in Accounting from Florida Atlantic University and a Bachelor of Arts degree in Economics from the University of Texas at Austin.

In respect of his additional responsibilities while serving as Interim Chief Executive Officer and President, Mr. Rosenbloom will receive an additional cash stipend of $10,000 per month, payable pro-rata at the end of his term as Interim Chief Executive Officer and President. Mr. Rosenbloom is considered an employee-at-will and is not subject to a separate employment agreement. Pursuant to Amendment No. 1 to Executive Offer Letter with Mr. Rosenbloom dated August 24, 2017, Mr. Rosenbloom is entitled to severance in the event the Company terminates his employment other than for cause or if Mr. Rosenbloom terminates his employment with good reason following a change of control of the Company. No new severance arrangement was entered into in connection with the Interim Chief Executive Officer change.

There are no arrangements or understandings between Mr. Rosenbloom and any other persons pursuant to which Mr. Rosenbloom was appointed as the Interim Chief Executive Officer. There are no family relationships between Mr. Rosenbloom and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The exhibit set forth in the following Exhibit Index is being filed herewith:

EXHIBIT INDEX

Exhibit	Description
10.1	Letter Agreement dated July 3, 2021 between PetMed Express, Inc. and Bruce S. Rosenbloom
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 6, 2021

PETMED EXPRESS, INC.
By:	/s/ Bruce S. Rosenbloom
	Name: Bruce S. Rosenbloom
Title: Chief Financial Officer

EX-10.1

Exhibit 10.1

Bruce,

As discussed, all of us on the board are really appreciative of your offer to step into the interim CEO and President role when Mendo leaves the business at the end of July.  We agree that this appointment will be well received by internal and external stakeholders, and that you are best positioned to take on many of Mendo’s responsibilities until such time as the new CEO is appointed and has started.

If you agree, you will be named interim CEO and President, effective July 31, 2021.  We will work with you to agree on the interim CEO operating protocol for running the business, including what support you will need from members of the board and any other internal or external support which will be required to ensure the day to day operations continue to run smoothly.  During the time you are the interim CEO, you also will remain the CFO and continue with those responsibilities, understanding that some support therefore may be delegated temporarily to other members of your team.  We do not anticipate that this appointment will be for a long duration as we hope to be able to appoint a permanent CEO in the next three months, although that appointment could be sooner (or later) than this.  In the meantime, however, we want to provide you with all the support necessary to ensure your tenure as interim CEO is successful.

We also want to recognize and compensate you for the additional responsibilities you will be taking on during this interim period.  We propose to pay you a cash stipend, effective upon your start date as interim CEO, equal to $10,000 per month for the time you serve in the interim role.  This stipend will begin to accrue on July 31 at the rate of $10,000 per month, will continue until the date that the new CEO starts, and will be prorated for any partial month of service.  The accrued stipend will be paid to you no later than 10 business days following the start date of the new CEO.

If the Company is unable to fill the CEO position with a permanent replacement, who is starting their tenure as CEO, by October 31, 2021, you may request amendment to certain terms of this agreement. Any amendment to this agreement would require Board approval.

If you agree to our proposal, please indicate your acceptance of it below, and confirm to me at your earliest convenience (an email acceptance is fine.)

We want to thank you again for your willingness to serve the company as the interim CEO until the appointment of a permanent CEO, and we look forward to supporting you in these increased responsibilities. 

  /s/ Gian Fulgoni                                                              

Gian Fulgoni

Chairman of the Board

Accepted on July 3, 2021:

  /s/ Bruce Rosenbloom                                                      

Bruce Rosenbloom

Chief Financial Officer & Treasurer

Exhibit 10.1 page 1 of 1

XML

Document And Entity Information	Jul. 03, 2021
Document Information [Line Items]
Entity, Registrant Name	PETMED EXPRESS, INC.
Document, Type	8-K
Document, Period End Date	Jul. 03, 2021
Entity, File Number	000-28827
Entity, Incorporation, State or Country Code	FL
Entity, Tax Identification Number	65-0680967
Entity, Address, Address Line One	420 South Congress Avenue
Entity, Address, City or Town	Delray Beach
Entity, Address, State or Province	FL
Entity, Address, Postal Zip Code	33445
City Area Code	561
Local Phone Number	526-4444
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	PETS
Security Exchange Name	NASDAQ
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0001040130